Cisanello Hospital Pisa: Tumor Surgery & Hospital Performance Report
“`html
pisa Hospital achieves Top Rankings in Italian Healthcare Performance for 2024
Table of Contents
Agenas, the National Agency for Regional Health Services, has released its 2024 performance data for Italian hospitals, placing Pisa University Hospital (Aoup) at the forefront in several key areas, particularly in surgical interventions for thyroid cancer and oncological care. This report assesses hospitals across seven clinical areas, highlighting PisaS excellence in oncology surgery, general surgery, and nervous system care.
Published December 11, 2024, at 16:53:19 (UTC)
Key Findings from the Agenas Report
The Agenas report evaluated Aoup across seven clinical areas: respiratory, nephrology, osteomuscular, cardiovascular, pregnancy and childbirth, oncology surgery, general surgery, and the nervous system. The hospital received ratings of “medium,” “high,” or “very high” in all areas, with particularly strong results in surgical specialties.
Surgical Excellence: Thyroid Cancer and Beyond
Pisa university Hospital leads Italy in the volume of surgical interventions for thyroid cancer, performing 1694 procedures – substantially more than the second-ranked hospital. This demonstrates a high level of specialization and experience in this area. The hospital also achieved a 30-day mortality rate of 0.28% for lung cancer patients, the lowest in Tuscany and well below the national average of 0.85% Agenas.
Clinical Area Performance Breakdown
Here’s a summary of Aoup’s performance across the seven clinical areas assessed by Agenas:
| Clinical Area | Rating |
|---|---|
| Respiratory | Medium |
| Nephrology | Medium |
| Osteomuscular | High |
| Cardiovascular | High |
| Pregnancy and Childbirth | High |
| Oncology Surgery | Very High |
| General Surgery | Very High |
| Nervous System | Very High |
Oncology Surgery: A Leading Center
Aoup’s oncology surgery department stands out as a center of excellence. The hospital’s performance in this area, combined with its low mortality rate for lung cancer, underscores its commitment to high-quality cancer care. Further details regarding specific cancer types treated and outcomes are expected to be released in subsequent Agenas reports.
